Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
AstraZeneca
Dow
Merck
Harvard Business School
Express Scripts

Last Updated: May 26, 2022

SLYND Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

When do Slynd patents expire, and when can generic versions of Slynd launch?

Slynd is a drug marketed by Exeltis Usa Inc and is included in one NDA. There are six patents protecting this drug and one Paragraph IV challenge.

This drug has fifty-one patent family members in twenty-seven countries.

The generic ingredient in SLYND is drospirenone. There are eleven drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the drospirenone profile page.

DrugPatentWatch® Generic Entry Outlook for Slynd

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be June 28, 2031. This may change due to patent challenges or generic licensing.

There is one Paragraph IV patent challenge for this drug. This may lead to patent invalidation or a license for generic production.

Indicators of Generic Entry

< Available with Subscription >

  Sign up for a Free Trial

Summary for SLYND
Drug patent expirations by year for SLYND
Drug Prices for SLYND

See drug prices for SLYND

DrugPatentWatch® Estimated Generic Entry Opportunity Date for SLYND
Generic Entry Date for SLYND*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Paragraph IV (Patent) Challenges for SLYND
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
SLYND Tablets drospirenone 4 mg 211367 1 2022-01-07

US Patents and Regulatory Information for SLYND

SLYND is protected by six US patents and one FDA Regulatory Exclusivity.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of SLYND is See Plans and Pricing.

This potential generic entry date is based on patent See Plans and Pricing.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting SLYND

Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: PREVENTION OF PREGNANCY IN FEMALES OF REPRODUCTIVE AGE

Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: PREVENTION OF PREGNANCY IN FEMALES OF REPRODUCTIVE AGE

Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: PREVENTION OF PREGNANCY IN FEMALES OF REPRODUCTIVE AGE

Synthetic progestogens and pharmaceutical compositions comprising the same
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Synthetic progestogens and pharmaceutical compositions comprising the same
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: PREVENTION OF PREGNANCY IN FEMALES OF REPRODUCTIVE AGE

FDA Regulatory Exclusivity protecting SLYND

NEW PRODUCT
Exclusivity Expiration: See Plans and Pricing

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Exeltis Usa Inc SLYND drospirenone TABLET;ORAL 211367-001 May 23, 2019 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Exeltis Usa Inc SLYND drospirenone TABLET;ORAL 211367-001 May 23, 2019 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Exeltis Usa Inc SLYND drospirenone TABLET;ORAL 211367-001 May 23, 2019 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for SLYND

When does loss-of-exclusivity occur for SLYND?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Patent: 1670
Estimated Expiration: See Plans and Pricing

Australia

Patent: 11273605
Estimated Expiration: See Plans and Pricing

Brazil

Patent: 2012033391
Estimated Expiration: See Plans and Pricing

Patent: 2019008317
Estimated Expiration: See Plans and Pricing

Canada

Patent: 03721
Estimated Expiration: See Plans and Pricing

Patent: 03062
Estimated Expiration: See Plans and Pricing

Patent: 61421
Estimated Expiration: See Plans and Pricing

Chile

Patent: 12003685
Estimated Expiration: See Plans and Pricing

Colombia

Patent: 40328
Estimated Expiration: See Plans and Pricing

Croatia

Patent: 0200155
Estimated Expiration: See Plans and Pricing

Denmark

Patent: 88114
Estimated Expiration: See Plans and Pricing

Patent: 32448
Estimated Expiration: See Plans and Pricing

Ecuador

Patent: 12012359
Estimated Expiration: See Plans and Pricing

Patent: 15032906
Estimated Expiration: See Plans and Pricing

Patent: 15032911
Estimated Expiration: See Plans and Pricing

Eurasian Patent Organization

Patent: 8680
Estimated Expiration: See Plans and Pricing

Patent: 1291372
Estimated Expiration: See Plans and Pricing

European Patent Office

Patent: 88114
Estimated Expiration: See Plans and Pricing

Patent: 32448
Estimated Expiration: See Plans and Pricing

Guatemala

Patent: 1200336
Estimated Expiration: See Plans and Pricing

Patent: 1200336A
Estimated Expiration: See Plans and Pricing

Patent: 1200336B
Estimated Expiration: See Plans and Pricing

Hungary

Patent: 47689
Estimated Expiration: See Plans and Pricing

Patent: 000016
Estimated Expiration: See Plans and Pricing

Japan

Patent: 10159
Estimated Expiration: See Plans and Pricing

Patent: 13529665
Estimated Expiration: See Plans and Pricing

Lithuania

Patent: 2021523
Estimated Expiration: See Plans and Pricing

Patent: 88114
Estimated Expiration: See Plans and Pricing

Mexico

Patent: 9952
Estimated Expiration: See Plans and Pricing

Patent: 4971
Estimated Expiration: See Plans and Pricing

Patent: 12014629
Estimated Expiration: See Plans and Pricing

Patent: 19004393
Estimated Expiration: See Plans and Pricing

New Zealand

Patent: 5176
Estimated Expiration: See Plans and Pricing

Norway

Patent: 20015
Estimated Expiration: See Plans and Pricing

Peru

Patent: 130780
Estimated Expiration: See Plans and Pricing

Patent: 161410
Estimated Expiration: See Plans and Pricing

Poland

Patent: 88114
Estimated Expiration: See Plans and Pricing

Portugal

Patent: 88114
Estimated Expiration: See Plans and Pricing

Serbia

Patent: 826
Estimated Expiration: See Plans and Pricing

Slovenia

Patent: 88114
Estimated Expiration: See Plans and Pricing

South Africa

Patent: 1209743
Estimated Expiration: See Plans and Pricing

South Korea

Patent: 2164693
Estimated Expiration: See Plans and Pricing

Patent: 2210982
Estimated Expiration: See Plans and Pricing

Patent: 130048227
Estimated Expiration: See Plans and Pricing

Patent: 170085604
Estimated Expiration: See Plans and Pricing

Patent: 190073598
Estimated Expiration: See Plans and Pricing

Patent: 210013663
Estimated Expiration: See Plans and Pricing

Spain

Patent: 77886
Estimated Expiration: See Plans and Pricing

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering SLYND around the world.

Country Patent Number Title Estimated Expiration
Denmark 3632448 See Plans and Pricing
European Patent Office 3632448 COMPOSITION PHARMACEUTIQUE COMPRENANT DE LA DROSPIRÉNONE ET ENSEMBLE CONTRACEPTIF (PHARMACEUTICAL COMPOSITION COMPRISING DROSPIRENONE AND CONTRACEPTIVE KIT) See Plans and Pricing
Ecuador SP12012359 COMPOSICIÓN FARMACÉUTICA QUE COMPRENDE DROSPIRENONA Y KIT ANTICONCEPTIVO See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for SLYND

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1380301 2009C/007 Belgium See Plans and Pricing PRODUCT NAME: DROSPIRENONE-ETHINYLESTRADIOL; AUTHORISATION NUMBER AND DATE: BE321386 20080811
2588114 LUC00227 Luxembourg See Plans and Pricing PRODUCT NAME: DROSPIRENONE; AUTHORISATION NUMBER AND DATE: 31332 20191022
2588114 CA 2020 00023 Denmark See Plans and Pricing PRODUCT NAME: DROSPIRENON; NAT. REG. NO/DATE: 61678 20191016; FIRST REG. NO/DATE: DK 61678 20191016
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Express Scripts
Baxter
Mallinckrodt
McKesson
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.